EXTON, Pa., Nov. 6, 2013 /PRNewswire/ -- ViroPharma
Incorporated (NASDAQ: VPHM) today announced it will present data
relating to the quality of life in patients with Hereditary
Angioedema (HAE) receiving nanofiltered C1 Inhibitor (C1 INH-nf)
replacement therapy for prophylaxis as well as data relating to the
Angioedema Clinical Epidemiology Testing Initiative for the study
of Hereditary Angioedema (ACET) at the 70th American College of
Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting.
The meeting will take place at the Baltimore Convention Center and the Hilton
Baltimore Hotel in Baltimore, Md.,
Nov. 7-11, 2013.
Saturday, November 9 and
Sunday, November 10: Embargo lifts November 8 at 12:01 am
EST
Poster Presentation
Poster
ID: P289
Presenter: William Lumry, MD, FAAAI,
FACAAI, Medical Director of Asthma and Allergy Research Associates
in Dallas, TX
Title: "Quality of Life in Patients with Hereditary Angioedema
Receiving Nanofiltered C1 Inhibitor for Prophylaxis: Results of a
Randomized, Placebo-Controlled, Crossover Study"
Authors Present: Saturday, November
9: 12:30 – 1:30 p.m. EST; and
Sunday, November 10: 12:00 – 1:00
p.m. EST
Location: Halls E & F, Baltimore Convention Center
Monday, November 11:
Podium
Presentation
Presenter: Marc
Riedl, MD, MS, Associate Professor of Medicine, Director of
Clinical Trials, Food, and Drug Allergy Care Center, Section Head,
Clinical Immunology and Allergy, UCLA David Geffen School
of Medicine in Los Angeles,
CA
Title: "Prevalence of Diagnosed and Undiagnosed Hereditary
Angioedema (HAE) in First-Degree Blood Relatives of Known Subjects
with Hereditary Angioedema"
Time: 1:00 p.m. – 1:15 p.m.
EST
Location: Rooms 316-317, Baltimore Convention Center
Monday, November 11:
Podium
Presentation
Presenter: H.
Henry Li, MD, PhD of the Institute for Asthma and Allergy in
Wheaton, MD
Title: "Comparison of Chromogenic and Enzyme-Linked Immunosorbent
Assay (ELISA) Testing Methods of Functional C1 Inhibitor (C1 INH)
in Diagnosing Hereditary Angioedema (HAE)"
Time: 1:30 p.m. – 1:45 p.m.
EST
Location: Rooms 316-317, Baltimore
Convention Center
About Cinryze® (C1 esterase inhibitor
[human])
Cinryze is a highly purified, pasteurized and
nanofiltered plasma-derived C1 esterase inhibitor product. In
the U.S. and Canada, Cinryze is
approved for routine prophylaxis (prevention) against angioedema
attacks in adolescent and adult patients with HAE. In the EU,
the product is approved for the treatment and pre-procedure
prevention of angioedema attacks in adults and adolescents with
hereditary angioedema (HAE), and routine prevention of angioedema
attacks in adults and adolescents with severe and recurrent attacks
of hereditary angioedema (HAE), who are intolerant to or
insufficiently protected by oral prevention treatments or patients
who are inadequately managed with repeated acute treatment.
Cinryze is for intravenous use only.
Severe hypersensitivity reactions to Cinryze may occur.
Thrombotic events have occurred in patients receiving Cinryze, and
in patients receiving off-label high dose C1 inhibitor
therapy. Monitor patients with known risk factors for
thrombotic events. With any blood or plasma derived product,
there may be a risk of transmission of infectious agents, e.g.
viruses and, theoretically, the CJD agent. The risk has been
reduced by screening donors for prior exposure to certain virus
infections and by manufacturing steps to reduce the risk of viral
transmission including pasteurization and nanofiltration.
The most common adverse reactions in clinical trials associated
with Cinryze were rash, headache, nausea, erythema, phlebitis and
local reactions at the injection site. Adverse events of
sinusitis and upper respiratory infection also were observed in
clinical trials. No drug-related serious adverse events (SAEs)
were reported in clinical trials.
Please visit http://www.viropharma.com/products/cinryze.aspx for
the full U.S. Prescribing Information; the prescribing information
for other countries can be found at www.viropharma.com.
About Hereditary Angioedema (HAE)
HAE is a rare,
severely debilitating, life-threatening genetic disorder caused by
a deficiency of C1 inhibitor, a human plasma protein. This
condition is the result of a defect in the gene controlling the
synthesis of C1 inhibitor. C1 inhibitor maintains the natural
regulation of the contact, complement, and fibrinolytic systems,
that when left unregulated, can initiate or perpetuate an attack by
consuming the already low levels of endogenous C1 inhibitor in HAE
patients. Patients with C1 inhibitor deficiency experience
recurrent, unpredictable, debilitating, and potentially life
threatening attacks of inflammation affecting the larynx, abdomen,
face, extremities and urogenital tract. Patients with HAE
experience approximately 20 to 100 days of incapacitation per year.
There are estimated to be at least 6,500 people with HAE
in the United States and at least 10,000 people in
the European Union.
For more information on HAE, visit the U.S. HAE Association's
website at www.haea.org and the HAEi's (International
Patient Organization for C1 Inhibitor Deficiencies) website
at www.haei.org.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical
company committed to developing and commercializing novel solutions
for physician specialists to address unmet medical needs of
patients living with diseases that have few if any clinical
therapeutic options. ViroPharma is developing a portfolio of
therapeutics for rare and Orphan diseases including C1 esterase
inhibitor deficiency, Friedreich's Ataxia, and adrenal
insufficiency; and recurrent C. difficile infection (CDI).
Our goal is to provide rewarding careers to employees, to create
new standards of care in the way serious diseases are treated, and
to build international partnerships with the patients, advocates,
and health care professionals we serve. ViroPharma's commercial
products address diseases including hereditary angioedema (HAE),
seizures and C. difficile-associated diarrhea (CDAD); for
full U.S. prescribing information on our products, please download
the package inserts at http://www.viropharma.com/Products.aspx; the
prescribing information for other countries can be found at
www.viropharma.com.
ViroPharma routinely posts information, including press
releases, which may be important to investors in the investor
relations and media sections of our company's web site,
www.viropharma.com. The company encourages investors to consult
these sections for more information on ViroPharma and our
business.
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements that involve a number of risks and uncertainties.
Forward-looking statements in this press release include statements
regarding the quality of life in patients taking Cinryze.
There can be no assurance that the data presented during the 70th
American College of Allergy, Asthma and Immunology (ACAAI) Annual
Scientific Meeting regarding Cinryze or testing of patients with
HAE is predictive of how Cinryze will perform in commercial
usage. In addition, the data that were discussed in this
abstract and presentation are subject to different interpretations.
The commercialization of pharmaceutical products is subject
to risks and uncertainties. Our actual results could differ
materially from those results expressed in, or implied by, these
forward-looking statements. These factors, and other factors,
including, but not limited to those described in our annual report
on Form 10-K for the year ended December 31,
2012 and 10-Q for the quarter ended March 31, 2013, June 30,
2013, and September 30, 2013
filed with the Securities and Exchange Commission, could cause
future results to differ materially from the expectations expressed
in this press release. The forward-looking statements contained in
this press release are made as of the date hereof and may become
outdated over time. ViroPharma does not assume any responsibility
for updating any forward-looking statements. These forward looking
statements should not be relied upon as representing our
assessments as of any date subsequent to the date of this press
release.
SOURCE ViroPharma Incorporated